Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Heparin to star at House hearings

Executive Summary

Events leading up to the distribution of contaminated heparin will be the focus of hearings tentatively scheduled for April 15 by House Energy & Commerce Oversight and Investigations Subcommittee. A week later, FDA Commissioner Andrew von Eschenbach will be asked to provide scenarios for revamping the agency's foreign drug plant inspection program. Seeking an end to the "unsafe" drug import saga, full committee chairman John Dingell, D-Mich., plans action this year on legislation that would assess annual drug import fees of $300 million to pay for inspection of drug imports (1"The Pink Sheet," Aug. 13, 2007, p. 21)

You may also be interested in...

FDA Chief Suggests Looking Outside Pharma For Tips On Quality Systems

FDA Commissioner Andrew von Eschenbach asked a group of medical products industry representatives July 9 to "think outside the box" to identify role models or lessons learned from other industries that could help address the challenges of drug import safety in a global marketplace

Inspection Of Rx Imports Would Climb Under Bill Setting $300 Mil. In User Fees

Drug import fees totaling $300 million each in fiscal years 2008 through 2012 would be authorized by a food and drug import safety bill being developed by House Energy and Commerce Committee Chairman John Dingell, D-Mich

Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease

Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity. 

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts